

PMDA NEWS RELEASE

For immediate Release: August 30, 2011

Media Inquiries: Masaaki Tsukano, +81-3-3506-9456

Title: MHLW/PMDA delegation visited China SFDA



MHLW/PMDA delegation headed by Dr. Hirayama, Councilor for Pharmaceutical Affairs of MHLW and Dr. Kondo, Chief Executive of PMDA visited China State Food and Drug Administration (SFDA) for the 2nd China-Japan bilateral meeting on August 23, 2011.

Mr. Wu Zheng, Deputy Commissioner, and other representatives from the Administration welcomed the Japanese delegation.

In the meeting, the participants confirmed the importance of cooperation between China and Japan, and agreed to further facilitate their cooperation.

Key achievements are as follows;

- The both sides exchanged information on clinical development and implementation of GCP
- The both sides agreed to establish joint working groups (WGs) as stipulated in the MOU between SFDA and MHLW.
- The both sides agreed on Rules and Procedures for the WGs

- The both sides determined four topics of pharmaceutical area to be dealt with by the WGs (separate WG for each topic): i.e. GCP, GMP, Training, and Clinical Development
- The both sides agreed to set up WGs on medical devices and cosmetics, whose works would be further considered and determined.
- The both sides agreed that the next bilateral meeting would be held in Japan in 2012

After the meeting, Japanese mission visited FDA's Center for Drug Evaluation (CDE), to meet Mr. Li Guoqing, Director of CDE, Dr. Zhang Peopei, Deputy Center Director, and other members. CDE and MHLW/PMDA representatives shared overviews of each side's activities, and eagerly exchanged views regarding drug review. The both sides agreed on stepping up mutual support and cooperation on technical matters.